20/20 Onsite

Home
United States
Boston, MA
20/20 Onsite

20/20 Onsite delivers comprehensive eye exams to businesses via a state-of-art mobile vision center.

20/20 Onsite (also known as 2020 Onsite) is the only provider solely dedicated to point-of-need eye assessments for clinical trials, proven to meet screening timelines, improve retention rates, and fast-track trials. This is a great way for companies to offer a unique, low-cost benefit to employees.

03/26/2026

Post-cataract complications like cystoid macular edema (CME) and post-operative ocular pain can impact vision after an otherwise successful surgery. These complications require dependable follow-up imaging to detect early and treat effectively.

For clinical trials studying new treatments for CME, consistent post-surgical monitoring is essential. Trials studying new treatments need repeated OCT imaging and visual testing, but asking patients recovering from surgery to travel repeatedly? That's when dropouts happen.

20/20 Onsite brings comprehensive post-surgical assessments directly to participants:

Mobile OCT for CME detection and monitoring
Visual acuity testing at convenient intervals
Detailed anterior and posterior segment exams
Flexible scheduling that respects recovery timelines

With 9% dropout rates versus the 30% industry standard, we help sponsors close the gap between surgical intervention and complete trial data.

Post-surgical trials demand post-surgical thinking. We're ready.

03/24/2026

Participant retention is not a motivation problem. It is an access problem.

In traditional trials, participants are often asked to travel long distances for short, specialized assessments. That burden compounds across visits and directly impacts retention.

20/20 Onsite addresses this at the infrastructure level.

By delivering ophthalmic assessments at or near where participants live, work, go to school, or gather, we reduce travel burden and make protocol adherence realistic over time.

Across verified 20/20 Onsite–supported trials:
Participant dropout rates are 9%, compared to an industry benchmark of ~30%
Average participant travel distance is significantly reduced
Retention improves because participation fits into real life, not because of added incentives
Retention improves when access improves.

Designing retention into your protocol starts with removing barriers, not adding reminders.

https://hubs.ly/Q046pgPY0

03/23/2026

See the trial through their eyes.

The optometrist who drove three hours to a rural site because the patient couldn't.
The one who recalibrated the tonometer at 6am before the first visit window opened.
The one who flagged the OCT drift at site 7 before the read center ever saw it.

They don't show up in the protocol.
They don't get named in the publication.

But without them, the data doesn't hold. The endpoint doesn't survive. The trial doesn't finish clean.

This World Optometry Day, the most important person in your trial might be the one your protocol assumes will just show up.

At 20/20 Onsite, they're the standard.
One call. End-to-end ownership.

https://hubs.ly/Q047WVXv0

03/19/2026

Before awarding new studies, sponsors and CROs frequently rely on ex*****on references, not just published outcomes. Data quality, consistency, and coordination shape those conversations.

20/20 Onsite protects both audiences:
Regulatory rigor that supports compliant submissions
Consistent ex*****on that stands up in reference checks
Single-partner accountability that eliminates operational ambiguity

Your endpoints do not just close a trial.

They shape your reputation for the next one.

https://hubs.ly/Q046pkcf0

03/17/2026

“We lost another participant.”
The reason? The visit required a 90-minute drive each way.
For most patients, that’s simply too far.

📊 Research backs it up: most patients are only willing to travel ~30 minutes or ~22 miles (PubMed).

At 20/20 Onsite, we decided to flip the model. Instead of waiting for patients to come to the site, we bring the site to them.

Our Mobile Vision Clinics deliver exams in patients’ own communities, reducing average travel distance by 82%.

When you remove travel as a barrier, participation rates rise, retention improves, and trials finish faster.

Close the gap. Capture the patient.

03/12/2026

The clinical trial diversity challenge isn't a recruitment problem—it's an access architecture problem.

When FDA guidance pushes for representative enrollment, the bottleneck isn't participant's willingness. It's the infrastructure assumption that everyone can reach fixed sites on rigid schedules.

Consider what's required to participate in a six-month ophthalmic study at a traditional center:
→ Transportation to unfamiliar locations
→ Time away from employment without flexibility
→ Childcare coordination for recurring visits
→ Navigation of institutional healthcare settings

These aren't minor inconveniences.

Mobile clinical infrastructure inverts the equation. Instead of asking communities to come to research, the research adapts to community realities. The result isn't just broader demographics in your enrollment data; it's retention rates that reflect genuine accessibility.

When participants can complete protocol visits near home, on schedules that accommodate their lives, with staff trained in cultural competency, the retention gap narrows dramatically.

This matters beyond compliance metrics. Medical interventions tested only on populations with the resources to access traditional sites produce evidence gaps that carry forward into real-world treatment efficacy.

Representative research requires representative infrastructure.

Details on operational models here: https://hubs.ly/Q0433vLr0

03/11/2026

Retention challenges are often addressed with added interventions.
Calls. Reminders. Incentives.

Yet the root cause is frequently unchanged: participation remains inconvenient.

20/20 Onsite improves retention by redesigning how care is delivered:
Assessments at the point of need
Predictable, standardized visits
Minimal coordination burden for participants

Retention improves when the path of least resistance is also the compliant one.

03/09/2026

There is something powerful about getting the entire team in one room.

Last week at our 20/20 Onsite all-hands meeting, we spent time reflecting on the past year, the milestones we reached, and the impact our team continues to make supporting clinical trials across the country.

More importantly, we aligned around where we are going next.
The energy, collaboration, and commitment to our mission was clear across every conversation.

Helping sponsors and CROs succeed while keeping patients at the center of what we do takes a special kind of team.

After last week, we are more aligned and energized than ever for the year ahead.

03/04/2026

Four months. That’s the average delay when a protocol amendment hits your trial.

And with over 40% of trials requiring one, those “small adjustments” can become million-dollar slowdowns.

Inconsistent site training, variable assessments, and equipment differences — they all add noise that forces rework.

At 20/20 Onsite, we eliminate that variability from the start.
Our standardized, mobile, point-of-need ocular assessments ensure every site, every visit, and every patient follow the same playbook.

The result? Cleaner data. Fewer amendments. Faster launches.

03/02/2026

When FDA-mandated ophthalmic assessments threaten to derail your trial, you need more than hope; you need an operational rescue playbook.

Join Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, for this exclusive on-demand webinar where she shares the proven strategies behind 85,000+ exams, 40+ trials, and 100% on-time delivery.

Learn how to identify enrollment stalls and capacity constraints early, apply immediate operational fixes for trial continuity, and know when to adjust versus redesign your protocols.

Plus, get access to a zero-commitment, 24-hour study assessment to evaluate your trial's current risk profile.

Watch now → https://hubs.ly/Q041LRHx0

02/26/2026

You don't need to redesign your entire protocol when ocular endpoints are at risk.

What you need is a systematic triage playbook you can deploy today.

In this on-demand webinar, Jessica McKenzie, VP of Life Sciences at 20/20 Onsite, shares the exact framework trusted by 40+ clinical trials to detect early warning signals, execute immediate triage, and deploy point-of-need capacity without compromising data quality or timelines.

Walk away with a reusable protocol checklist and access to a zero-commitment, 24-hour study assessment.

Click here to watch the webinar → https://hubs.ly/Q03Zxm290

02/25/2026

Site Initiation Visits (SIVs) are where ocular endpoints either get set up for clean, consistent ex*****on, or quietly pick up the “small problems” that turn into timeline slips, data variability, and avoidable rework later.

A few SIV focuses that matter more than most teams expect:

- Training and certification: BCVA, OCT, IOP, these are not “plug and play.” Standardization is the work.
- Device validation and readiness: calibration, documentation, and traceability need to be audit-ready from day one.
- Vendor coordination and data flow: if device data to CRF/EDC is not mapped early, you will feel it at go-live.

If you are building in ocular endpoints, treat the SIV as your operational design review, not a checkbox.

Read the full breakdown here. https://hubs.ly/Q041h4L70

Address

Boston, MA
02110

Website

http://www.2020onsite.com/

Alerts

Be the first to know and let us send you an email when 20/20 Onsite posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to 20/20 Onsite:

Shortcuts

Want your practice to be the top-listed Clinic in Boston?